Table 2.
Possibility of obtaining a therapeutic exposure in the treatment of invasive aspergillosis for the different posaconazole formulations. Data represent values calculated for an AUC/MIC ratio of 200. Due to the linear pharmacokinetics, values can be divided by two for an AUC/MIC ratio of 100 in the prophylaxis setting. Table adapted from [3•]
MIC minimum inhibitory concentration, EUCAST EUropean Committee on Antifungal Susceptibility Testing, AUC area under the concentration time curve, C min trough concentration, S susceptible, I intermediate, R resistant
aFor MIC values of 0.25 mg/l, AUC/MIC ratios cannot be reached with the standard dose as the registered dose for intravenous use is 300 mg, whereas the registered dose for the tablets is 400 mg [23]
